5.3 Bronchodilators, Corticosteroids, Insulin & Oral Antidiabetic Agents

ACSM Certified Clinical Exercise Physiologist ACSM-CEP

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 The ACSM-CEP Role, Job Definition & Scope of Practice 1.2 Exam Format, Domain Weights & Scoring 1.3 Eligibility, Study Planning & Test-Day Strategy

2 Applied Exercise Physiology & Metabolic Calculations

Bioenergetics & Energy Systems (ATP-PC, glycolytic, oxidative) Acute Cardiorespiratory & Metabolic Responses to Aerobic Exercise Responses to Resistance Exercise & Chronic Training Adaptations ACSM Metabolic Equations, METs & Interpreting VO₂ / RER / Ventilatory Threshold

3 Pathophysiology of Clinical Populations

3.1 Coronary Artery Disease, Myocardial Infarction & Revascularization (PCI/CABG) 3.2 Heart Failure, Valvular Disease & Cardiac Rhythm Disorders 3.3 Hypertension, Dyslipidemia & Peripheral Artery Disease 3.4 Pulmonary Disease: COPD, Asthma & Restrictive/Interstitial Disorders 3.5 Diabetes, Metabolic Syndrome & Obesity 3.6 Renal Disease & Musculoskeletal/Orthopedic Conditions 3.7 Neuromuscular, Neurological & Cognitive Conditions (stroke, MS, Parkinson's, SCI) 3.8 Neoplastic, Immunologic & Hematologic Disorders (cancer, HIV/AIDS, anemia)

4 Clinical ECG Interpretation

4.1 ECG Leads, Waveforms, Rate & Rhythm Determination 4.2 Arrhythmias & Conduction Blocks 4.3 Ischemia, Injury & Infarction (ST changes, exercise-induced) 4.4 Drug & Electrolyte ECG Effects; Resting/Exercise Monitoring Setup & Lead Placement

5 Pharmacology for the Clinical Exercise Physiologist

5.1 Beta-Blockers, Calcium-Channel Blockers & Nitrates 5.2 RAAS Agents, Diuretics, Antiarrhythmics, Lipid-Lowering & Antithrombotic Drugs 5.3 Bronchodilators, Corticosteroids, Insulin & Oral Antidiabetic Agents 5.4 Medication Effects on HR/BP & Exercise Response; Dose/Meal/Dialysis Timing

6 Patient Assessment (Domain I, 18%)

6.1 Medical Records, HIPAA/HITRUST, Charting & Physician Referral 6.2 Patient Interview, Medical History & Medication Reconciliation 6.3 Resting Vital Signs, Body Composition & Resting ECG 6.4 Preparticipation Health Screening & Level of Monitoring (PAR-Q+, ACSM algorithm, ACC/AHA · GOLD · ADA · AACVPR) 6.5 Assessing Patient Goals, Readiness & Psychosocial Status

7 Clinical Exercise Testing (Domain II, 18%)

Submaximal Aerobic Tests (treadmill, cycle, step, 6-minute walk) Musculoskeletal Fitness, Mobility & Balance Testing Maximal Symptom-Limited GXT: Protocols, Contraindications & ECG Prep Test Termination: Relative & Absolute Indications Interpreting & Reporting Results (ECG response, RPP, claudication, Duke Treadmill Score, VO₂/RER/AT)

8 Exercise Prescription for Clinical Populations (Domain III, 22%)

FITT-VP Principles, Progression & Prescription Foundations Ex Rx for Cardiovascular Disease (CAD, HF, HTN, PAD, post-revascularization) Ex Rx for Pulmonary Disease (COPD, asthma; breathing techniques, supplemental O2) Ex Rx for Diabetes, Metabolic Syndrome & Obesity Ex Rx for Musculoskeletal, Neuromuscular, Neoplastic & Other Conditions Communicating Intensity (THR, RPE, talk test), Monitoring & Modifying the Prescription

9 Exercise Training & Leadership (Domain IV, 24%)

9.1 Discussing the Training Plan, Clinician & Patient Expectations/Goals 9.2 Instructing & Modifying Exercise Modes (cardiorespiratory, strength/endurance, flexibility, coordination, agility) 9.3 Patient Monitoring & Supervision During Exercise (telemetry, oximetry, glucometry, ECG) 9.4 Contraindications to Training & Modifying Recommendations 9.5 Documenting Clinical Status, Reporting Adverse Events & Interdisciplinary Coordination

10 Education & Behavior Change (Domain V, 13%)

10.1 Behavioral-Health Screening & Recognizing Distress (PHQ-9, Beck, SF-36; referral) 10.2 Patient Education, Health Literacy & Disease Self-Management 10.3 Motivational Interviewing & Behavior-Change Theories (Transtheoretical, HBM, Social Cognitive, Five-A's) 10.4 Promoting Adherence, Self-Efficacy, Relapse Prevention & Social Support

11 Legal, Professional & Emergency Management (Domain VI, 5%)

11.1 Emergency Equipment, Crash Cart Inspection & Emergency Procedures 11.2 CPR/AED/BLS/ACLS, Universal Precautions & EMS Activation 11.3 Scope of Practice, Legal/Ethical Standards, Liability/Negligence, Informed Consent & Professional Organizations (ACSM/AACVPR/AHA)

5.3 Bronchodilators, Corticosteroids, Insulin & Oral Antidiabetic Agents

Key Takeaways Explain This Topic AI

Beta-2 agonist bronchodilators (albuterol, salmeterol) can cause a modest, expected rise in exercise heart rate as a stimulant side effect, not a cardiac warning sign.

Insulin and sulfonylureas carry the highest exercise-related hypoglycemia risk of any diabetes medication class; ADA guidance calls for checking glucose before, during, and after exercise.

SGLT2 inhibitors carry a distinct risk of euglycemic diabetic ketoacidosis with prolonged or intense exercise, dehydration, or illness — glucose may look normal even during a true ketoacidosis episode.

Systemic (oral) corticosteroids carry a substantially higher hyperglycemia and myopathy risk than inhaled corticosteroids, though inhaled steroids are not entirely risk-free with long-term use.

A concurrent beta-blocker can blunt the adrenergic warning signs of hypoglycemia (tachycardia, tremor), making early recognition harder in patients on both drug classes.

Last updated: July 2026

Bronchodilators, Corticosteroids, Insulin & Oral Antidiabetic Agents

Quick Answer: Beta-2 agonist bronchodilators can modestly raise exercise heart rate as a side effect — not a sign of a cardiac problem. Insulin and sulfonylureas carry the highest exercise-related hypoglycemia risk of any diabetes medication class, while SGLT2 inhibitors carry a distinct risk of euglycemic diabetic ketoacidosis during prolonged, intense exercise.

Bronchodilators

Beta-2 agonists are the backbone of bronchodilator therapy: short-acting agents (SABA — albuterol) are used for quick relief and, importantly, pre-exercise prophylaxis in patients prone to exercise-induced bronchospasm (EIB); long-acting agents (LABA — salmeterol, formoterol) are maintenance therapy, always paired with an inhaled corticosteroid in asthma. Because beta-2 agonists can cross-react with beta-1 receptors, especially at higher doses, they commonly cause tachycardia, palpitations, and tremor . A CEP should expect a modestly elevated exercise heart rate in a patient using these medications and recognize it as a known drug effect rather than mistaking it for deconditioning or an emerging cardiac event.

Anticholinergics/muscarinic antagonists (ipratropium, short-acting; tiotropium, long-acting) are a mainstay for COPD and have minimal cardiac stimulant effect — their main side effect is dry mouth. Confirm every EIB-prone patient carries a rescue inhaler at each session, and treat post-exertional cough, wheeze, or dyspnea as a possible sign of undertreated EIB worth reporting — not just being "out of shape." Timing also matters clinically: a SABA taken 15-30 minutes before exercise is generally more effective at preventing EIB symptoms than one taken after symptoms have already started, so confirming a patient's pre-exercise inhaler routine during the interview is a useful, low-effort safety check.

Corticosteroids

Inhaled corticosteroids (ICS — fluticasone, budesonide) are first-line controller therapy for asthma, frequently combined with a LABA. Systemic absorption is low but not zero: long-term daily ICS use has been associated in observational data with some hyperglycemia risk and myopathy symptoms , so it should not be treated as entirely risk-free. Oral/systemic corticosteroids (prednisone), used for exacerbations or chronic inflammatory conditions, carry a substantially higher risk profile: hyperglycemia (which can transiently worsen glycemic control and interact with insulin dosing in diabetic patients), corticosteroid myopathy (proximal muscle weakness, more common with higher-dose or long-term oral use), fluid retention, elevated blood pressure, increased infection risk, and reduced bone density. A patient on a burst or chronic course of oral steroids may show transient hyperglycemia and reduced tolerance for resistance training — this calls for closer monitoring, not the assumption that a steroid course changes nothing.

Insulin & Sulfonylureas: The Hypoglycemia Risk

Insulin (all formulations) and sulfonylureas (glipizide, glyburide, glimepiride) or meglitinides carry the highest exercise-related hypoglycemia risk of any diabetes medication class. Exercise independently increases insulin sensitivity and non-insulin-mediated glucose uptake into muscle, compounding the medication's glucose-lowering effect — sometimes for hours after the session ends. Current ADA Standards of Care guidance calls for checking blood glucose before, during (for longer sessions), and after exercise in patients on these agents, keeping fast-acting carbohydrate available, and considering a pre-exercise snack when glucose is low-normal or insulin action is near its peak. Injecting insulin into a limb about to be heavily exercised can also speed absorption and should be avoided. Recognize hypoglycemia symptoms (shakiness, sweating, confusion, irritability) — and remember from earlier in this chapter that a concurrent beta-blocker can blunt the adrenergic warning signs , making hypoglycemia harder to catch early in these patients.

Metformin, GLP-1 Agonists & SGLT2 Inhibitors

Metformin carries low hypoglycemia risk when used alone; its rare but serious risk is lactic acidosis, with caution warranted in renal impairment or dehydration — relevant after prolonged, intense exercise or in heat. GLP-1 receptor agonists (semaglutide, liraglutide) also carry low hypoglycemia risk alone, though GI side effects (nausea) can affect exercise tolerance or hydration status. SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) carry low hypoglycemia risk alone but a distinct risk of euglycemic diabetic ketoacidosis — ketoacidosis with a normal or only mildly elevated glucose reading that can delay recognition. This risk rises specifically with prolonged or intense exercise (e.g., endurance events), dehydration, low-carbohydrate intake, or illness. Counsel patients on SGLT2 inhibitors on adequate hydration and on recognizing DKA symptoms (nausea, vomiting, abdominal pain, fatigue) even when a glucose check looks reassuring.

Medication Class vs. Exercise-Relevant Risk

Medication Class Hypoglycemia Risk with Exercise Key Exercise-Related Safety Note
Insulin High Monitor glucose pre/during/after; time exercise relative to peak action
Sulfonylureas/meglitinides High Same monitoring; risk further masked by concurrent beta-blockers
Metformin Low (alone) Rare lactic acidosis risk if dehydrated or renally impaired
GLP-1 agonists Low (alone) GI side effects may affect hydration/tolerance
SGLT2 inhibitors Low (alone) Euglycemic DKA risk with intense/prolonged exercise, dehydration
Beta-2 agonist bronchodilators Not applicable Can raise exercise HR — don't mistake for a cardiac event

Oral/systemic corticosteroids Not applicable (raises glucose) Hyperglycemia and myopathy risk with prolonged use